AGIOS PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Revenue
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Increase (Decrease) in Deferred Revenue of -$10.64 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-08-02
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$7.50M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$3.14M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$6.43M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$8.96M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2017 was -$26.57M, a 116.02% decline from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2016 was $165.85M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2015 was -$14.05M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2014 was -$19.23M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$10.64M 10-Q · filed 2018-08-02 | -$17.07M derived: sum of 3 quarters · filed 2018-08-02 | -$26.03M derived: sum of 4 quarters · filed 2018-08-02 |
| 2018-03-31 | -$3.14M 10-Q · filed 2018-05-04 | -$9.57M derived: sum of 2 quarters · filed 2018-05-04 | -$18.53M derived: sum of 3 quarters · filed 2018-05-04 | -$27.79M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-12-31 | -$6.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | -$15.39M derived: sum of 2 quarters · filed 2018-02-14 | -$24.65M derived: sum of 3 quarters · filed 2018-08-02 | -$26.57M 10-K · filed 2018-02-14 |
| 2017-09-30 | -$8.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$18.22M derived: sum of 2 quarters · filed 2018-08-02 | -$20.14M 10-Q · filed 2017-11-01 | -$40.29M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-06-30 | -$9.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$11.18M 10-Q · filed 2018-08-02 | -$31.33M derived: sum of 3 quarters · filed 2018-08-02 | -$35.98M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | -$1.92M 10-Q · filed 2018-05-04 | -$22.07M derived: sum of 2 quarters · filed 2018-05-04 | -$26.72M derived: sum of 3 quarters · filed 2018-05-04 | $169.81M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | -$20.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | -$24.80M derived: sum of 2 quarters · filed 2018-02-14 | $171.74M derived: sum of 3 quarters · filed 2018-02-14 | $165.85M 10-K · filed 2018-02-14 |
| 2016-09-30 | -$4.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $191.88M derived: sum of 2 quarters · filed 2017-11-01 | $185.99M 10-Q · filed 2017-11-01 | $181.47M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-06-30 | $196.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $190.65M 10-Q · filed 2017-08-08 | $186.12M derived: sum of 3 quarters · filed 2018-02-14 | $183.01M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-03-31 | -$5.89M 10-Q · filed 2017-05-04 | -$10.42M derived: sum of 2 quarters · filed 2018-02-14 | -$13.53M derived: sum of 3 quarters · filed 2018-02-14 | $11.45M derived: sum of 4 quarters · filed 2018-02-14 |
| 2015-12-31 | -$4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | -$7.63M derived: sum of 2 quarters · filed 2018-02-14 | $17.35M derived: sum of 3 quarters · filed 2018-02-14 | -$14.05M 10-K · filed 2018-02-14 |
| 2015-09-30 | -$3.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $21.87M derived: sum of 2 quarters · filed 2016-11-03 | -$9.52M 10-Q · filed 2016-11-03 | -$16.31M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-30 | $24.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$6.41M 10-Q · filed 2016-08-08 | -$13.20M derived: sum of 3 quarters · filed 2017-02-16 | -$28.34M derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-31 | -$31.39M 10-Q · filed 2016-05-09 | -$38.18M derived: sum of 2 quarters · filed 2017-02-16 | -$53.32M derived: sum of 3 quarters · filed 2017-02-16 | -$44.35M derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | -$6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | -$21.93M derived: sum of 2 quarters · filed 2017-02-16 | -$12.96M derived: sum of 3 quarters · filed 2017-02-16 | -$19.23M 10-K · filed 2017-02-16 |
| 2014-09-30 | -$15.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$6.17M derived: sum of 2 quarters · filed 2015-11-06 | -$12.44M 10-Q · filed 2015-11-06 | -$18.71M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $8.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $2.70M 10-Q · filed 2015-08-07 | -$3.57M derived: sum of 3 quarters · filed 2016-02-26 | -$9.83M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | -$6.27M 10-Q · filed 2015-05-11 | -$12.54M derived: sum of 2 quarters · filed 2016-02-26 | -$18.80M derived: sum of 3 quarters · filed 2016-02-26 | -$25.07M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | -$6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$12.54M derived: sum of 2 quarters · filed 2016-02-26 | -$18.80M derived: sum of 3 quarters · filed 2016-02-26 | -$25.07M 10-K · filed 2016-02-26 |
| 2013-09-30 | -$6.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$12.54M derived: sum of 2 quarters · filed 2014-11-07 | -$18.80M 10-Q · filed 2014-11-07 | -$25.07M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | -$6.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$12.54M 10-Q · filed 2014-08-07 | -$18.80M derived: sum of 3 quarters · filed 2015-02-24 | -$25.07M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | -$6.27M 10-Q · filed 2014-05-09 | -$12.54M derived: sum of 2 quarters · filed 2015-02-24 | -$18.80M derived: sum of 3 quarters · filed 2015-02-24 | |
| 2012-12-31 | -$6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$12.54M derived: sum of 2 quarters · filed 2015-02-24 | -$25.07M 10-K · filed 2015-02-24 | |
| 2012-09-30 | -$6.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$18.80M 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | -$12.54M 10-Q · filed 2013-09-05 | |||
| 2011-12-31 | -$1.80M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |